[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587615":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":67,"collaborators":26,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":26,"studyType":84,"phases":85,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"The Methodist Hospital Research Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm","EXPERIMENTAL","Dexamethasone 20 mg",[13],"Drug: Dexamethasone Sodium Phosphate Injection 20 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Arm","ACTIVE_COMPARATOR","Dexamethasone 4 mg",[19],"Drug: Dexamethasone Sodium Phosphate Injection 4mg",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexamethasone Sodium Phosphate Injection 20 mg","dexamethasone 20 mg diluted in 50 mL of normal saline administered by intravenous drip after induction of anesthesia",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Dexamethasone Sodium Phosphate Injection 4mg","dexamethasone 4 mg diluted in 50 mL of normal saline administered by intravenous drip after induction of anesthesia",[15],[32],{"name":33,"affiliation":5,"role":34},"Monica Morgan, MD","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Farida Tufail","CONTACT","713-269-0186","ftufail@houstonmethodist.org",{"name":42,"role":38,"phone":26,"phoneExt":26,"email":43},"Johnny Su, MD","jssu@houstonmethodist.org",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Houston Methodist Hospital","RECRUITING","Houston","Texas","77005","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-95.36327,29.76328,{"lat":57,"lon":56},[60,61,62,65],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"name":63,"role":64,"phone":26,"phoneExt":26,"email":26},"Rose Khavari, MD","SUB_INVESTIGATOR",{"name":66,"role":64,"phone":26,"phoneExt":26,"email":26},"Kathleen Kobashi, MD",{"type":34,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Monica Morgan","Assistant Professor of Clinical Urology","100587615","phase-1-dexamethasone-for-ureteral-stent-symptoms-dusts-100587615",false,"NCT06930690","Dexamethasone for Ureteral STent Symptoms (DUSTS)","Dexamethasone for Ureteral STent Symptoms (DUSTS): A Randomized, Double-blinded Controlled Study","DUSTS","Inclusion Criteria:\n\n1. Age 18-70 years old\n2. Patients who are undergoing unilateral retrograde ureteroscopy (semi-rigid or flexible) with planned ureteral stent placement for treatment of renal\u002Fureteral stones\n3. Patients who can read and understand English\n4. Patients who can follow up post-operatively within 7 days at Houston Methodist Hospital\n\nExclusion Criteria:\n\n1. Untreated UTI\n2. HbA1c ≥6.5 on preoperative testing\n3. Patients with prior diagnosis of any type of diabetes mellitus\n4. Patients with immunosuppression, including chronic corticosteroid use\n5. Patients with bleeding disorder\n6. Patients with chronic liver disease, cirrhosis, and liver failure.\n7. Patients taking strong CYP3A4 inducers or inhibitors within two weeks of screening\n8. Chronic opioid analgesic use\n9. Congenital renal abnormalities (e.g. pelvic kidney, ureteric duplication) that may impair stent placement\n10. Concurrent genitourinary malignancy\n11. Urinary diversion\n12. Renal transplantation\n13. History of interstitial cystitis\u002Fpainful bladder syndrome, prostatitis, pelvic pain due to other conditions (e.g. endometriosis)\n14. Neurologic disorder (e.g. spinal cord injury, multiple sclerosis, spina bifida)\n15. Pregnant or breastfeeding\n16. Patients with cognitive impairments or untreated psychiatric illness","ALL","18 Years","70 Years",{"count":82,"type":83},70,"ESTIMATED","INTERVENTIONAL",[86,87],"PHASE1","PHASE2","The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones. The main question it aims to answer is:\n\n1\\) Does high-dose steroid change the quality of life score on day 2 after surgery\n\nResearchers will compare high-dose of dexamethasone (20 mg) to a standard dose of dexamethasone (4 mg) to see if a higher dose of the drug will help with urinary symptoms and pain\n\nParticipants will:\n\n1. randomly receive 20 mg or 4 mg of dexamethasone (20 mg) at the time of surgery\n2. fill out a questionnaire day 1 and day 2 after surgery\n3. fill out a medication diary for one week after surgery\n4. visit the clinic on day 2 after surgery for checkup\n5. visit the clinic on day 4-7 after surgery for check up",[90],"Ureteral Stent-Related Symptom",[92,93,94,90],"Ureteral Stent","Nephrolithiasis","Ureteral Stent Discomfort","2026-05-27",{"date":97,"type":98},"2026-05-29","ACTUAL",{"date":100,"type":83},"2026-06",{"date":102,"type":83},"2027-04",{"name":5,"class":6},1]